Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women
- PMID: 18275275
- DOI: 10.1086/526496
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women
Abstract
Background: Trichomoniasis vaginalis is the most common nonviral sexually transmitted infection (STI) worldwide, with a particularly high prevalence in regions of human immunodeficiency virus (HIV) endemicity. However, its impact as a cofactor for HIV acquisition is poorly understood.
Methods: Samples from 213 women who experienced HIV seroconversion (cases) during a longitudinal study involving 4450 women in Uganda and Zimbabwe were matched with samples from HIV-uninfected women (controls). All samples underwent polymerase chain reaction (PCR) analysis for Trichomonas vaginalis DNA. For cases, analyzed samples were from the visit in which HIV seroconversion was detected and the visit preceding detection of seroconversion; for controls, one analyzed sample was from the visit matched by follow-up duration to the cases' seroconversion visit, and the other sample was from the visit immediately preceding the matched visit.
Results: The prevalence of T. vaginalis infection before HIV infection was 11.3% in cases and 4.5% in controls (P = .002). In multivariable analysis controlling for hormonal contraception, other STIs, behavioral, and demographic factors, the adjusted odds ratio for HIV acquisition was 2.74 (95% confidence interval, 1.25-6.00) for T. vaginalis-positive cases. The presence of behavioral risk factors for HIV infection, study recruitment from a referral population at high-risk for HIV, primary sex partner-associated risk for HIV infection, and herpes simplex virus type 2 seropositivity were also predictive of incident HIV infection.
Conclusions: T. vaginalis infection is strongly associated with an increased risk for HIV infection in this general population of African women. Given the high prevalence of T. vaginalis infection in HIV-endemic areas, T. vaginalis control may have a substantial impact on preventing HIV acquisition among women.
Comment in
-
Trichomonas vaginalis infection: can we afford to do nothing?J Infect Dis. 2008 Feb 15;197(4):487-9. doi: 10.1086/526498. J Infect Dis. 2008. PMID: 18275270 Free PMC article. No abstract available.
-
Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who use drugs.J Infect Dis. 2008 Feb 15;197(4):503-9. doi: 10.1086/526497. J Infect Dis. 2008. PMID: 18275272
Similar articles
-
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women.Sex Transm Dis. 2010 Jul;37(7):460-6. doi: 10.1097/OLQ.0b013e3181cfcc4b. Sex Transm Dis. 2010. PMID: 20562586 Clinical Trial.
-
Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics.Sex Transm Dis. 2008 May;35(5):484-8. doi: 10.1097/OLQ.0b013e3181644b9c. Sex Transm Dis. 2008. PMID: 18360314 Clinical Trial.
-
Disentangling contributions of reproductive tract infections to HIV acquisition in African Women.Sex Transm Dis. 2009 Jun;36(6):357-64. doi: 10.1097/OLQ.0b013e3181a4f695. Sex Transm Dis. 2009. PMID: 19434010
-
Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition.Am J Reprod Immunol. 2011 Feb;65(2):89-98. doi: 10.1111/j.1600-0897.2010.00902.x. Am J Reprod Immunol. 2011. PMID: 20678168 Review.
-
Insights into trichomoniasis as a result of highly sensitive molecular diagnostics screening in a high-prevalence sexually transmitted infection community.Expert Rev Anti Infect Ther. 2013 Aug;11(8):845-63. doi: 10.1586/14787210.2013.814429. Epub 2013 Aug 14. Expert Rev Anti Infect Ther. 2013. PMID: 23944153 Review.
Cited by
-
Associations between intravaginal practices and incidence of sexually transmitted infections and bacterial vaginosis among women enrolled in the dapivirine vaginal ring trial (The Ring Study) in southwestern Uganda: a retrospective secondary analysis.BMJ Open. 2024 Apr 8;14(4):e079497. doi: 10.1136/bmjopen-2023-079497. BMJ Open. 2024. PMID: 38589266 Free PMC article. Clinical Trial.
-
Role of cytoneme structures and extracellular vesicles in Trichomonas vaginalis parasite-parasite communication.Elife. 2023 May 2;12:e86067. doi: 10.7554/eLife.86067. Elife. 2023. PMID: 37129369 Free PMC article.
-
Unusual Cell Structures and Organelles in Giardia intestinalis and Trichomonas vaginalis Are Potential Drug Targets.Microorganisms. 2022 Nov 2;10(11):2176. doi: 10.3390/microorganisms10112176. Microorganisms. 2022. PMID: 36363768 Free PMC article. Review.
-
Induction of apoptosis by essential oil of Dracocephalum kotschyi on Trichomonas vaginalis.Vet Med Sci. 2023 Mar;9(2):1008-1016. doi: 10.1002/vms3.977. Epub 2022 Oct 17. Vet Med Sci. 2023. PMID: 36253818 Free PMC article.
-
VPS32, a member of the ESCRT complex, modulates adherence to host cells in the parasite Trichomonas vaginalis by affecting biogenesis and cargo sorting of released extracellular vesicles.Cell Mol Life Sci. 2021 Dec 24;79(1):11. doi: 10.1007/s00018-021-04083-3. Cell Mol Life Sci. 2021. PMID: 34951683 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
